Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 3/20 | 0.39 |
| ▸ | PRF1 | P14222 | 2/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | PRKCG | P05129 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421975 | 0.93 | FFAR1 (0.36) | ACACAPRF1PFKFB3FFAR1DPP4 | |
| SCHEMBL4552509 | 0.82 | ROCK2 (0.40) | ACACAPFKFB3CDC7PLK4CHEK1 | |
| SCHEMBL6583442 | 0.80 | HTR7 (0.42) | ROCK2PRKACAPRKCDROCK1DYRK1A | |
| SCHEMBL221772 | 0.76 | HTR7 (0.61) | MAPTHTR7 | |
| SCHEMBL6585074 | 0.75 | ACACA (0.50) | ACACAPFKFB3 | |
| SCHEMBL421976 | 0.73 | PLAU (0.36) | ROCK2PRKACASYKPRKCDROCK1 | |
| SCHEMBL29899251 | 0.73 | NOS3 (0.54) | PDPK1SRCIRAK4HTR7 | |
| SCHEMBL420575 | 0.73 | NOS3 (0.56) | MAP4K4ABL1EGFRLCKFYN | |
| SCHEMBL222026 | 0.71 | KDM4E (0.54) | SRC | |
| SCHEMBL250790 | 0.71 | NOS3 (0.52) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | ACACA 2861/4885PRF1 3072/4885PFKFB3 4521/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | ACACA 2124/4885PRF1 1734/4885PFKFB3 1632/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | ACACA 1605/4885PRF1 3640/4885PFKFB3 3830/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | ACACA 686/4885PRF1 4717/4885PFKFB3 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.